ADPT (Adaptive Biotechnologies Corporation) may reap gains as insiders became active recently


Adaptive Biotechnologies Corporation’s recent filing unveils that its Chief Operating Officer ADAMS R MARK unloaded Company’s shares for reported $18275.0 on Jan 10. In the deal valued at $8.58 per share,2,130 shares were sold. As a result of this transaction, ADAMS R MARK now holds 113,518 shares worth roughly $ 0.94 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, ADAMS R MARK sold 995 shares, generating $8,458 in total proceeds. Upon selling the shares at $8.50, the Chief Operating Officer now owns 115,648 shares.

Before that, PISKEL KYLE sold 959 shares. Adaptive Biotechnologies Corporation shares valued at $8,506 were divested by the Principal Accounting Officer at a price of $8.87 per share. As a result of the transaction, PISKEL KYLE now holds 46,706 shares, worth roughly $0.39 million.

Scotiabank initiated its Adaptive Biotechnologies Corporation [ADPT] rating to a Sector outperform in a research note published on Friday, January 05, 2023; the price target was $15. PT values the company’s stock at a premium of 44.53 to its Friday closing price. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in late December from “a Neutral” to “an Overweight”. Credit Suisse began covering ADPT with “an Underperform” recommendation on August 25, 2022. Piper Sandler started covering the stock on June 03, 2022. It rated ADPT as “a Neutral”.

Price Performance Review of ADPT

On Friday, Adaptive Biotechnologies Corporation [NASDAQ:ADPT] saw its stock fall -3.70% to $8.32. On the same session, the stock had its day’s lowest price of $8.18, but rose to a high of $8.49. Over the last five days, the stock has lost -13.60%. Adaptive Biotechnologies Corporation shares have risen nearly 8.90% since the year began. Nevertheless, the stocks have fallen -35.40% over the past one year. While a 52-week high of $15.21 was reached on 01/18/23, a 52-week low of $5.95 was recorded on 01/03/23. SMA at 50 days reached $8.76, while 200 days put it at $8.52. A total of 0.69 million shares were traded, compared to the trading of 0.77 million shares in the previous session.

Levels Of Support And Resistance For ADPT Stock

The 24-hour chart illustrates a support level at 8.17, which if violated will result in even more drops to 8.02. On the upside, there is a resistance level at 8.48. A further resistance level may holdings at 8.64. The Relative Strength Index (RSI) on the 14-day chart is 41.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.45, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.64%. Stochastics %K at 12.55% indicates the stock is a buying.

How much short interest is there in Adaptive Biotechnologies Corporation?

A steep rise in short interest was recorded in Adaptive Biotechnologies Corporation stocks on Jan 30, 2023, dropping by -1.16 million shares to a total of 4.75 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 5.91 million shares. There was a decline of -24.42%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.90% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.79.

Adaptive Biotechnologies Corporation [ADPT] – Who Are The Largest Shareholders?

In filings from Viking Global Investors LP, it is revealed that the company now owns 29,993,708 shares, or roughly 20.97% of the outstanding ADPT shares. Additionally, The Vanguard Group, Inc. increased 1.05% of its stake after which the total value it holdings stand at $107,663,402. Over the last quarter, BlackRock Fund Advisors purchased 1,497,892 shares of Adaptive Biotechnologies Corporation, while ARK Investment Management LLC bought -135,374 shares. At present, Nikko Asset Management Americas, is holding 5,352,315 shares valued at $49.62 million. Blue Water Life Science Advisors owned 3,030,434 shares of the company at the time of its most recent 13F filing, worth $28.09 million.

According to FactSet, Adaptive Biotechnologies Corporation’s share price will average $12.63 in the next year, based on opinions of analysts polled by the firm. This is up nearly 50.46 percent from its previous closing price of $8.64. Analysts expect Adaptive Biotechnologies Corporation stock to reach the higher price of $15.00, while the lowest price estimate is $7.00. However, 10 analysts have rated ADPT stock as an Overweight in their predictions for 2023. The most recent change occurred on February 16, 2022 when JP Morgan resumed its ‘”an Overweight”‘ rating for the stock and retained the price target to $50.


Please enter your comment!
Please enter your name here